Ireland
--:--IST
Enrolling by invitation Not applicable

Robotic Therapy Hybridized With Mirror Therapy in Stroke Rehabilitation

NCT06777654 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2025-03-31
Last updated
2025-03-27

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

Robotic therapy (RT)Mirror therapy (MT)Dose-matched control intervention

Robotic therapy (RT): The Bi-Manu-Track (BMT) robot will be provided as the robotic practice. The BMT can be switched from the bilateral practice modules involving bilateral upper limbs to the unilateral module involving the affected upper limb. According to the group assignment, participants will practice the unilateral or bilateral module of BMT training.

Mirror therapy (MT): The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.

Dose-matched control intervention: Participants in the control group will receive therapist-mediated rehabilitation per session.

Study summary

The goal of this clinical trial is to compare the effects of three groups: (1) unilateral robotic therapy with computerized visual feedback plus unilateral innovative mirror therapy, (2) bilateral robotic therapy with computerized visual feedback plus bilateral innovative mirror therapy, and (3) dose-matched conventional rehabilitation as the control. The investigators will also study the factors predictive of treatment success, identify key predictors of clinical improvement, and distinguish patient profiles most likely to benefit from each regimen. The findings of this clinical trial are expected to advance knowledge about the synergistic effects of unilateral and bilateral hybrid programs. The predictive study of treatment outcomes will inform patient selection in precision rehabilitation toward personalized stroke management.

Eligibility

Sex
ALL
Min age
30 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: (1) a first ever-stroke≧3 months and less than 2 years, (2) age range between 30 to 80 years, (3) baseline Fugl-Meyer Assessment-Upper Extremity subscale (FMA-UE) between 18 to 56, (4) no excessive muscle spasticity of the affected extremities (Modified Ashworth Scale \< 3 at any joints), (5) able to follow examiners' commands and study instructions (Montreal Cognitive Assessment score≧22), and (6) no fracture of upper extremities within the past 3 months, and (7) no participation in any other experimental rehabilitation or drug studies during study period of this project. Exclusion Criteria: (1) acute inflammation and pain, (2) receiving botulinum toxin injections within the past 3 months, and (3) concomitant neurologic, neuromuscular or orthopedic conditions that may interfere with participation in this research.

Primary outcome measure(s)

  • Fugl-Meyer Assessment-Upper Extremity subscale (FMA-UE) — Baseline, 6 weeks, and 18 weeks

Trial sites (2)

FacilityCityRegionStatus
Wan Fang Hospital, Taipei Medical University Taipei Taiwan
National Taiwan University Hospital Taipei, Taiwan Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06777654 on ClinicalTrials.gov ↗ ← All trials in Taiwan